Plasma mepivacaine concentrations in patients undergoing third molar surgery.

Abstract

Local anaesthetic-related systemic toxicity mainly results from elevated plasma concentrations of these drugs. We hypothesized that intraoral injection of submaximal doses of mepivacaine does not lead to toxic levels of this drug in blood. This study evaluated the plasma levels of mepivacaine in third molars surgeries. Twenty-one patients were randomly assigned into two groups: group I (two unilateral third molars; submaximal dose of mepivacaine 108mg with epinephrine 54μg) and group II (four third molars; submaximal dose of mepivacaine 216mg with epinephrine 108μg). Blood samples were collected before anaesthesia, and 5, 10, 15, 20, 30, 40, 60, 90 and 120min after anaesthesia. Individual peak plasma concentrations ranged 0.77-8.31μg/mL (group I) and from 2.36-7.72μg/mL (group II). An increase in the average dose of mepivacaine from 1.88±0.12mg/kg (group I) to 3.35±0.17mg/kg (group II) increased the mean mepivacaine peak plasma levels from 2.33±0.58 to 4.01±0.69μg/mL, respectively. Four patients obtained plasma levels of mepivacaine above the threshold for toxicity (5μg/mL). Toxic levels of mepivacaine are possible, even when a submaximal dose is used. A twofold increase in the dose of mepivacaine caused the mean peak plasma concentration to increase proportionally, indicating that they may be predicted based on the relation of dose per bodyweight.